ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novartis will pay Ionis Pharmaceuticals $60 million as part of a pact to develop a new drug for cardiovascular disease driven by lipoprotein(a). Ionis previously discovered pelacarsen, an antisense molecule that is intended to treat the disease, and Novartis is testing it in a Phase 3 clinical trial. The new compound is a potential follow-on to pelacarsen, Ionis says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter